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Abstract
Background The structural similarity between low molecular weight
protamine (LMWP), prepared by enzymatic digestion of protamine, and
HIV-TAT protein transduction peptide suggested the feasibility of LMWP
as an efficient carrier for delivering therapeutic genes while alleviating the
cytotoxicity of currently employed gene carriers.
Methods LMWP was prepared by enzymatic digestion of protamine with
thermolysine. The prepared LMWP peptide and TAT peptide, as well as
their complexes with plasmid DNA (pDNA), were examined for cellular
uptake behaviors by using confocal microscopy and flow cytometry. The
complexation of pDNA and LMWP was monitored by gel retardation test as
well as size and zeta potential measurements, and was then further assessed
by DNase I protection assay. The transfection efficiency of pDNA/LMWP was
examined by varying the pDNA content and charge ratio in the complex, and
then compared with that of pDNA/PEI. Cytotoxicity induced by pDNA/LMWP
and pDNA/PEI was also examined.
Results Prepared LMWP showed similar transcellular localization behavior
and kinetics to those of TAT, and efficiently transferred the pDNA into
nucleus and cytoplasm in a short time period. The size and zeta potential
of the pDNA/LMWP complex were 120 nm and 30 mV, respectively, which
were adequately suitable for cellular uptake. After forming the complex,
LMWP appeared to effectively protect pDNA against DNase I attack. The
pDNA/LMWP complex showed significantly enhanced gene transfer than
both naked pDNA and the pDNA/PEI complex, while exhibiting a markedly
reduced cytotoxicity than that of the pDNA/PEI complex.
Conclusions The present study suggested that LMWP could be a useful and
safe tool for enhancing delivery of bioactive molecules and therapeutic DNA
products into cells when applied in gene therapy. Copyright  2003 John
Wiley & Sons, Ltd.
Keywords low molecular weight protamine; TAT peptide; transcellular
localization; gene transfer; gene therapy
Introduction
Gene therapy offers significant opportunities to treat various kinds of life-
threatening and gene-related diseases by producing, in vivo, the essential
biological agents or stopping abnormal cell functions such as genetic failure
or uncontrollable proliferation [1–4]. Therapeutic application of the gene
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products, however, has been limited due to concerns
related to such gene products including their instability
in body fluids, lack of cell targeting specificity, rapid
degradation by nucleases, and poor transfection efficiency
[5,6]. In this regard, the primary efforts in gene therapy
have been focused on enhancing gene expression and
reducing the cytotoxicity of the therapy [7–16]. A
number of potential gene delivery carriers including
viral vectors [7,8], liposomes [9,10], peptides [11,12]
and cationic polymers [13–16] have been widely
investigated. Viral vectors such as adenovirus and
retrovirus have been proven to yield a superior gene
transfection efficiency in vivo, yet their uses demand
further exploration and careful assessments due to the
adverse effects such as immunogenicity, toxicity and
mutagenesis caused by the cell-infecting virus [8]. On
the other hand, nonviral gene carriers such as cationic
liposomes [9,10], peptides (e.g. protamine) [11,12] and
synthetic polymers (e.g., poly (L-lysine) (PLL)) [13,14],
polyethyleneimine (PEI) [15,16]) are shown to introduce
a significantly reduced immunogenicity than the viral
vectors in vitro, but their in vivo applications are
hampered by the exceedingly low transfection efficiency
and sometimes the poor biocompatibility, as well as
by the cytotoxicity of the polymeric carriers and/or
their degradation products [17]. The quest for an
effective and yet nontoxic gene carrier thus remains
ongoing.
Recently, we reported the development of low
molecular weight protamine (LMWP) fragments as
possible nontoxic substitutes of protamine in clinical
heparin neutralization [18–20]. Such LMWP fragments
were derived directly from native protamine sulfate by
enzymatic digestion with thermolysine. In a previous
investigation, these LMWP peptides, which displayed a
rich arginine content in their amino acid compositions,
were found to retain a nearly complete heparin-
neutralizing ability and yet with a significantly less toxicity
in vivo [18–20]. Aside from their potential in condensing
DNA (Note: the use of protamine in gene delivery has been
proposed elsewhere), the LMWP peptides also carried
significant structural similarity to the protein transduction
domain (PTD) of the HIV-TAT protein. As reported in
the literature [21–23], the PTD of the TAT protein,
TAT(48–60), comprised a highly basic and hydrophilic
peptide consisting of six arginine and two lysine residues
in its 13 amino acid sequence. At a concentration as low
as 0.1 µM, this TAT peptide was shown to translocate
through the cell membranes within a period of 5 min
[21,22]. In addition, by genetic or chemical hybridization
of this TAT peptide to a variety of biologically active
species, including proteins, peptides, DNA, and even
magnetic nanoparticles [23–25], this TAT peptide was
shown to be able to facilitate a rapid internalization
of all of such attached species into various cell types.
Since like the highly basic TAT, LMWP also possesses
10 arginine residues in its structure, it was anticipated
that LMWP would possess similar functions as TAT in
translocating active agents inside cells. Indeed, in our
preliminary studies, we found that LMWP was almost
equally potent as TAT in mediating cell translocation
of its attached species (data not shown). Based on its
significantly reduced toxicity, LMWP may be used in gene
therapy to overcome the current toxicity-related limitation
of the gene carriers. Unlike TAT, however, the toxicity
profiles of LMWP have already been fully established.
Animal studies conducted in our laboratory demonstrated
that LMWP was not toxic [18–20], immunogenic or
antigenic [18–20]. An additional advantage of using
LMWP as the gene carrier is that, unlike TAT which
must be synthesized chemically, LMWP can be readily
produced from native protamine in mass quantities,
thereby significantly reducing the costs and the production
period.
Hence, in the study reported here, we explored the
possibility and potential of utilizing this nontoxic, TAT-
like LMWP peptide as an effective carrier for gene delivery.
The in vitro capability of LMWP in cell trafficking,
condensing DNA, translocalizing DNA inside the cells,
protecting DNA from DNase I degradation, transfecting




Salmin protamine, thermolysine and 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were
purchased from Sigma (St. Louis, MO, USA). Psv-β-gal
plasmid vector (6821 bp) and the o-nitrophenyl-β-D-
galactopyranoside (ONPG) assay system were obtained
from Promega (Madison, WI, USA). Fetal bovine
serum (FBS), phosphate-buffered saline (PBS), 0.25%
(w/v) trypsin-EDTA, Roswell Park Memorial Institute
medium (RPMI 1640), Dulbecco’s modified essential
medium (DMEM), penicillin and streptomycin were
purchased from Gibco-BRL (Gaithersburg, MD, USA).
The BCA protein assay reagent was from Pierce
(Rockford, IL, USA). The peptide containing the TAT
(CYGGYGRKKRRQRRRR) sequence was synthesized by
the Protein Core Facility at University of Michigan.
Polyethyleneimine (PEI) was from Polyscience Co. (St.
Louis, MO, USA). Hoechst 33 342 dye was purchased from
Molecular Probes, Inc. (Eugene, OR, USA). Fluorescein-
labeled plasmid DNA (pGeneGripTM) was obtained from
Gene Therapy System Inc. (San Diego, CA, USA). All of
the solvents used were analytical grade and water was
distilled and deionized.
Preparation of LMWP peptide
The enzymatic method employed for the preparation
of LMWP has been described in previous publications
[18–20]. In brief, thermolysin and protamine were mixed
and incubated for 30 min at room temperature, followed
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by quenching of the thermolysin activity with 50 mM
EDTA. Thermolysin was then removed by ultrafiltra-
tion using a YM3 membrane (MWCO 3000), and the
filtrate was subject to lyophilization. Since the lyophilized
LMWP preparation contained a mixture of small pep-
tide impurities, it was further purified by using hep-
arin affinity chromatography. A total of five peptides,
denoted TDSP 1–5 according to the order of elution
from the heparin column, were obtained. The molec-
ular weight and amino acid sequence of each isolated
LMWP peptide were determined by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) analysis, which was performed by
the Protein and Carbohydrate Research Center at the
University of Michigan. Among the five fractions, TDSP
5 (VSRRRRRRGGRRRR) was utilized in all subsequent
studies.
Fluorescence labeling
Peptides were labeled with fluorescein isothiocyanate
(FITC) at their N-terminals. In brief, the peptide solution
(pH 9.3, carbonate buffer) was reacted, in 1 : 2 molar
ratio, with a FITC solution (in dimethylformamide)
overnight in the dark at room temperature. Reaction was
monitored by high-performance liquid chromatography
(HPLC) of the absorbance change at 215 nm of the peptide
peak. The labeled peptides were purified by HPLC (purity:
>95%), lyophilized in the dark, and then stored at −20 ◦C
in the dark until further use.
Cell lines
The 293T human embryonic kidney transformed cells
were obtained from ATCC (Rockville, MD, USA). They
were grown and maintained at 37 ◦C in humidified 5%
CO2 in DMEM medium containing 10% FBS, 100 units/ml
penicillin-streptomycin mixture, and 2.2 mg/ml sodium
bicarbonate.
Amplification and purification of the
plasmid
The pSV-β-galactosidase plasmid (Promega) was ampli-
fied in the Escherichia coli strain DH5α (Gibco-BRL,
Gaithersburg, MD, USA) and purified using the Qiagen
plasmids Maxi Kits (Qiagen, Valencia, CA, USA). Purity of
the plasmid DNA was confirmed by the OD260/OD280 ratio
and the intensity of corresponding DNA fragments in gel
electrophoresis following treatment of the plasmid DNA
with a restriction enzyme. The concentration of the plas-
mid DNA was determined using the ratio that 1 (OD260)
was equivalent to 50 µg of DNA. The plasmid DNA was
stored at −20 ◦C until use. For visualization of plas-
mid DNA inside the cells, FITC-labeled β-galactosidase
plasmid DNA was utilized.
Preparation of plasmid DNA/peptide
complexes
The pDNA/LMWP complexes were prepared by mixing
various amounts of LMWP (increasing from 1–20 µg in
10 µl water) with plasmid (1 µg in 10 µl water). The
solution was allowed to stand for 30 min at 20 ◦C for
complex formation. By mixing with various amounts of
LMWP, the pDNA/LMWP complexes comprising different
charge ratios (−/+) ranging from 1 : 1 to 1 : 20 were
obtained. Formation of the pDNA/LMWP complexes was
monitored by 1.0% agarose gel electrophoresis using DNA
molecular markers. Following electrophoresis, the gels
were stained with 0.5 µg/ml ethidium bromide for 45 min
and analyzed on a UV illuminator to identify the locations
of DNA. In addition, the pDNA/LMWP complexes were
also examined for their size and zeta potential by using
a Zeta-PALS (Brookhaven Instruments Corp., Holtsville,
NY, USA) zetameter. All such experiments were carried
out at 25 ◦C, pH 7.0 and 677 nm in wavelength, and a
constant angle of 15◦. The particle size was presented as
the effective mean diameter.
FITC-labeled pDNA/LMWP and pDNA/TAT complexes
were prepared by mixing LMWP or TAT with FITC-
labeled pDNA (pGeneGripTM) encoding β-galactosidase
at a charge ratio (−/+) = 1 : 10. The solutions were
incubated at 20 ◦C for 30 min for complex formation.
Confocal laser scanning microscopy
Peptide internalization
Cells were plated in Lab-Tek (4-well) chambered
slideglasses at 1 × 104 cells/chamber in a volume of
1 ml. After complete adhesion, the culture medium was
removed. The FITC-labeled LMWP or TAT was then added
to the cells at a final peptide concentration of 0.2 µM.
Following 1 h incubation, cells were washed three times
and fixed in 1% (w/v) paraformaldehyde in PBS for
20 min at room temperature. The fixed cells were washed
again with PBS, mounted in a PBS/glycerin mixture (1 : 1,
v/v) containing 2.5% DABSCO as an antifading agent,
and kept at 4 ◦C for at least 1 h before being examined by
confocal microscopy.
DNA/peptide complex internalization
FITC-labeled free pDNA, pDNA/LMWP complex, or
pDNA/TAT complex was added to cells (104 cells)
cultured in Lab-Tek chambered slideglasses. After 1 h
incubation, cells were washed with PBS and further
incubated with 50 ng/ml Hoechst 33 342 dye in PBS
supplemented with 1% (v/v) FBS at room temperature for
15 min. Cells were then washed with PBS, and fixed with
1% paraformaldehyde for 20 min. The fixed cells were
washed again and mounted with PBS/glycerol containing
antifading agent. Confocal laser scanning microscopy was
carried out using an inverted LSM 510 laser scanning
microscope (Carl Zeiss, Gottingen, Germany) equipped
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with a Plan-Apochromat 63 × 1.4 N.A. or 40 × 1.4 N.A.
lens. The laser was set at 488 (blue) and 543 (yellow)
to produce the excitation wavelengths for fluorescein and
rhodamine, respectively. Hoechst dye fluorescence was
collected by the laser tuned to 790 nm/400 nw for two-
photon excitation of the dye. Z-series were taken of a 1 to
2 micron optical section at 2-µm intervals.
Flow cytometric analyses
The 293T cells were seeded at a density of 1 × 106 cells
per well in 6-well plates in 1.5 ml culture medium. One
day later, the cells were washed and incubated with
FITC-labeled peptides for 0.5, 1, 4, 10 and 24 h. For
studies related to the complexes, FITC-labeled pDNA,
pDNA/LMWP, or pDNA/TAT complex was incubated with
the above 293T cells for 1 h. After incubation, the cells
were washed with PBS, trypsinized, and washed. The cells
were then fixed with 1% paraformaldehyde and washed
with PBS. Analysis was conducted on a FACScaliber
flow cytometer (Beckton Dickinson, San Jose, CA, USA)
equipped with a 488 nm air-cooled argon laser. The filter
settings for emission were 530/30 nm bandpass (FL1) for
FITC. The fluorescence of 10 000 vital cells was acquired
and data was visualized in logarithmic mode.
Stability of the LMWP/DNA complexes
The charge ratio (−/+) used in the preparation of
the pDNA/LMWP complex was controlled at 1 : 2. After
complex formation, DNase I (50 units, Gibco BRL) was
added to the complex suspension, and the solution was
incubated at 37 ◦C for 60 min. Naked pDNA was used
as the control. At time intervals of 0, 10, 20, 40, 60,
and 80 min during incubation, 50 µl of the complex
suspension were withdrawn, mixed with 75 µl of the
stop solution (4 M ammonium acetate, 20 mM EDTA, and
2 mg/ml glycogen), and then placed on ice. The pDNA
was dissociated from LMWP by adding 37 µl 1.0% SDS to
the complex suspension and then heating the mixture at
65 ◦C overnight. The pDNA was extracted and precipitated
by treating the solution mixture with phenol/chloroform
and ethanol several times. The precipitated DNA pellet
was then dissolved in 10 µl of TE buffer and subjected to
1.0% agarose gel electrophoresis.
In vitro transfection
The 293T cells were seeded at a density of 2 × 106
cells/dish in 35-mm culture dishes, and incubated for
24 h before the addition of transfection complexes.
Transfection mixtures were prepared separately for LMWP
and PEI, whereas PEI served as a control. pDNA/LMWP
(or pDNA/PEI) complexes were prepared by mixing
10 µg of pSV-β-galactosidase and various amounts of
LMWP (or PEI) in 500 µl of serum-free DMEM medium,
followed by incubating the mixtures for 30 min at room
temperature. The molecular weight of PEI for transfection
and cytotoxicity studies was either 2000 or 25 000 Da.
Five hundred microliters of LMWP/DNA complex were
then added to each well, and the cells were incubated
for 4 h at 37 ◦C in a 5% CO2 incubator. After a 6-
h exposure, the transfection mixtures were replaced
with 2 ml of fresh DMEM medium containing 10% FBS
and 100 units/ml penicillin-streptomycin mixture. Cells
were incubated for an additional 2 days at 37 ◦C before
analysis of β-galactosidase activity. To perform the β-
galactosidase assay, cells were washed, lysed with 300 µl
of lysis reagent (25 mM glycylglycine, 15 mM MgSO4,
4 mM EDTA, 1% Triton X-100, 1 mM DTT, 1 mM PMSF),
and centrifuged at 13 000 rpm for 5 min. The activity of
β-galactosidase in the supernatants was then measured
using the ONPG assay described previously [26]. This
ONPG assay was based on cleavage of the β-bond of
ONPG by β-galactosidase, resulting in the production of
a yellowish o-nitrophenol molecule. The reaction was
quenched using 1 M Na2CO3. Samples were analyzed
by measuring the absorbance at 420 nm with a Bio-Rad
microplate reader (BioRad Laboratories, USA). Aside from
β-galactosidase activity, the supernatants were measured
for their protein concentrations using a BCA protein assay
kit (BioRad Laboratories).
Cytotoxicity assay
Evaluation of the cytotoxicity of LMWP and pDNA/LMWP
complexes was conducted by using the MTT assay. In
general, the 293T cells were seeded at a density of
1.0 × 104 cells/well in a 96-well flat-bottomed microassay
plate (Falcon Co., Beckton Dickinson, Franklin Lakes, NJ,
USA) and incubated for 24 h. The LMWP or pDNA/LMWP
complex solution was then added and the mixture was
incubated for another 48 h at 37 ◦C. Parallel experiments
were conducted using PEI and pDNA/PEI complex as the
controls. At the end of the transfection experiment, the
medium was replaced with 200 µl of fresh DMEM medium
without serum, and 120 µl of 2 mg/ml MTT solution in
PBS were then added. After incubation for an additional
4 h at 37 ◦C, the MTT-containing medium was removed,
and 200 µl of dimethyl sulfoxide (DMSO) were added
to dissolve the formazan crystals formed by live cells.
Absorbance was measured at 570 nm. The cell viability
(%) was calculated according to the following equation:
Cell viability (%) = (OD570(sample))/(OD570(control)) × 100
where OD570(sample) and OD570(control) represent measure-
ments from wells treated with LMWP/DNA and PBS
buffer, respectively.
Statistical analysis
All measurements were conducted in triplicate and
expressed as mean ± standard deviation. Student’s t-test
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was utilized to compare the statistical significance of
the transfection efficiency and cytotoxicity between the
LMWP and PEI complex.
Results
Synthesis of LMWP
Thermolysin-digested protamine was fractionated into
five distinct fractions, which were denoted ‘Thermolysine-
Digested Segmented Protamine, TDSP 1–5’ according to
their orders of elution from the heparin column [18–20].
Table 1 shows the amino acid sequences and molecular
weights of the TDSP 1–5 peptides and TAT. Among those
fractions, TDSP 4 and TDSP 5 displayed the highest degree
of heparin neutralization and the lowest degree of toxicity
[18–20]. In the current study, TDSP 5 was utilized since
it possessed almost the same molecular weight as TAT,
and the two clusters of cationic amino acid sequences,




















Figure 1. Confocal microscopic observation of the cells treated with either LMWP (left panel) or TAT (right panel) peptide for
15 min (A) and 1 h (B). Time course of the cellular uptake of LMWP and TAT is measured by flow cytometric analysis with cells
incubated with each of the peptides for a predetermined time period (C); uptake of TAT () and of LMWP (ž). The cellular uptake
of each peptide was estimated from the mean fluorescent signal of 10 000 cells collected
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Table 1. Amino acid sequence and molecular weight of
each fraction of the LMWPs
Fraction Amino acid sequence Molecular weight
TDSP 1 PRRRR 740.8
TDSP 2 PRRRRR 896.9
TDSP 3 PRRRRSSRRP 1325.2
TDSP 4 ASRRRRRGGRRRR 1695.5
TDSP 5 VSRRRRRRGGRRRR 1879.7
TAT CYGGYGRKKRRQRRRR 1900.0
Cellular uptake of LMWP
Prior to investigating the capacity of LMWP as a gene
carrier, we first examined the ability of LMWP to
transverse into the cells, and to determine its subcellular
localization. Internalization of the LMWP was monitored
by confocal microscopy after 15 and 60 min incubation
of the peptides with the cells. Figure 1 shows that LMWP
internalized into the cell as efficiently as the TAT peptides.
In less than 15 min, LMWP was found to localize mainly
in the cytosol, with some existing in the perinuclear
site (Figure 1A). After 1 h, both peptides were seen to
translocate through cell membranes and accumulate in
the cytoplasm and nucleus, with a large fraction of both
internalized peptides seen in the nucleus (Figure 1B).
Almost all of the cell population exhibited a high
fluorescent intensity, demonstrating the unprecedented
efficiency in cell internalization by both LMWP and TAT.
To more precisely understand this cell internalization
event mediated by these peptides, quantification of the
internalized peptides was carried out. The cellular uptake
of each peptide was measured by the mean fluorescent
signal for 10 000 cells collected. The rate of cellular
uptake of TAT turned out to be slightly faster than
LMWP; however, the difference was not that significant
(Figure 1C). Indeed, a virtually similar cell uptake kinetics
between LMWP and TAT was observed. These results
indicated that LMWP possessed a similar cell-penetration
capability to TAT, rendering it feasible to serve as a carrier
for effective gene delivery. In this regard, complexation
of LMWP with pDNA was conducted, and the formed
complex was further examined for its cell-translocating
ability.
Complex formation of LMWP with DNA
A gel retardation study was performed to confirm the
formation of complexes between LMWP and pDNA.
One microgram of pSV-β-galactosidase plasmid was
mixed with various amounts of LMWP to yield differ-
ent charge ratios (−/+) between pDNA and LMWP.
The pDNA/LMWP complexes were analyzed by 1.0%
agarose gel electrophoresis. As seen in Figure 2A, the
pDNA/LMWP complexes were completely retarded in
their migration at the 1 : 1 charge ratio (−/+) between
pDNA and LMWP. These results suggested that LMWP was
able to effectively condense plasmid DNA into complex at
the charge ratio of 1 : 1 (−/+), as the migration of the
formed pDNA/LMWP complex on agarose gel was con-
siderably retarded due to charge neutralization and the
increase in the overall molecular size. These findings are
in good agreement with those observed by other investi-
gators [13,14], indicating that LMWP formed a condensed
complex with pDNA as effectively as any of the currently
used cationic polymeric gene carriers [13,14].
Figure 2(B) and 2(C) show the size distribution
and zeta potential of the pDNA/LMWP complex,









































Figure 2. (A) Gel retardation assay. The pDNA/LMWP complexes
were prepared at various charge ratios and incubated at
room temperature and left for 20 min for complex formation.
The complexes were analyzed by 1% (w/v) agarose gel
electrophoresis. (B) Particle size of the complexes of plasmid
DNA with LMWP as a function of the charge ratio (+/−) between
LMWP and plasmid DNA. Data are presented as mean ± standard
deviation. The plasmid DNA concentration was 2 µg/ml. (C) Zeta
potential of complexes of plasmid DNA with LMWP as a function
of the charge ratio (+/−) between LMWP and plasmid DNA.
Data are presented as mean ± standard deviation. The plasmid
DNA concentration was 2 µg/ml
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respectively. While the naked DNA has a size of 2300 nm,
the pDNA/LMWP complex produced particles with
significantly reduced size of around 120 nm at the charge
ratio (−/+) 1 : 2 (Figure 2B). The charge neutralization
occurred before the charge ratio (peptide/DNA) 1 : 1;
therefore, particle size decreased from 2330 nm to
176 nm, 129 nm, 89 nm, as the charge ratio increased
from 0 : 1 to 1 : 1, 2 : 1 and 5 : 1, respectively. The
particle size was increased at a charge ratio of 10 : 1
(131 nm) due to an aggregation; however, it was still
a reasonable enough size to be carried into the cells.
When the charge ratio increased to over 20 : 1, however,
the particle size was increased to 400 nm (data not
shown) due to aggregation which resulted in a low
transfection efficiency. In addition, surface zeta potential
significantly increased after the formation of the plasmid
DNA/LMWP complex due to charge neutralization, then
it was gradually increased to +35 mV when the charge
ratio reached 10 : 1. Unlike the naked plasmid DNA that
showed a charge of −80 mV on its surface, complexation
with LMWP rendered the surface charge positive (35 mV;
Figure 2C). In this regard, results from size distribution
and zeta potential measurements not only confirmed
the complex formation between pDNA and LMWP, but
also conferred the event of cellular uptake of the
complex particles. It has been well documented that
particles with a size below 200 nm and a surface charge
around 20–30 mV yield the most preferable cell uptake
in vitro [14].
Cellular uptake of the pDNA/LMWP
complex
The LMWP peptide was evaluated for its ability to
facilitate cellular pDNA delivery when forming the
condensed complex. FITC-labeled pDNA was mixed with
either LMWP or TAT with a charge ratio (−/+) = 1 : 10.
As shown in Figure 3A, there was virtually no cellular
uptake of free FITC-labeled pDNA. In contrast, incubation
of LMWP with FITC-pDNA promoted internalization
Fluorescence Superimposition
pDNA/LMWP complex pDNA/TAT complex
Naked pDNA
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Figure 3. Cellular uptake of FITC-labeled pDNA into 293T cells. Left panels indicate confocal microscopy using a Zeiss Axiovert
with 60× objective. (A) FITC-labeled pDNA with no peptide complex as a negative control; (B) FITC-labeled pDNA complex with
LMWP; (C) FITC-labeled pDNA complex with TAT peptide as a positive control. (D) Flow cytometric analysis of FITC-labeled pDNA
in the cells in dependence on the formation of the complexes with the peptides (ordinate indicates the number of cells and abscissa
indicates fluorescent intensity). The concentration of pDNA was 5 µg/ml, and the incubation time at 37 ◦C was 1 h
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of FITC-labeled pDNA in the cells; with a large
fraction of pDNA being seen to localize in the nucleus
(Figure 3B). This enhanced cell uptake of pDNA was also
seen by using the pDNA/TAT complex, which served
as a control (Figure 3C). For both LMWP and TAT
complexes, fluorescein was visualized in both the nucleus
and cytoplasm. Superimposition of the two images by
fluorescein and Hoechst 33 342 dye (for nuclear staining)
clearly demonstrated a nuclear localization of the pDNA.
As reported previously, TAT can facilitate the delivery
of its associated molecules into cells in a short time
period [21,22]. Confocal microscopy data in combination
with the flow cytometric analysis (Figure 3D) confirmed
that TAT mediated pDNA cell internalization within 1 h.
Flow cytometric analysis also indicated that LMWP had a
similar capability in promoting transcellular localization
of pDNA as that of TAT (Figure 3D). Overall, results from
the cell uptake studies clearly demonstrated that LMWP
could effectively deliver pDNA in the cytosol by forming
a complex.
DNase I protection assay
Since pDNA can be easily degraded by nucleases either
in the cytosol or circulation, instability of pDNA remains
one of the obstacles for the delivery of therapeutic genes
in vitro or in vivo [13,14]. DNase I is known to be a major
nuclease present in the serum or cytosol. Therefore, for
a successful systemic gene delivery, it is essential for
the carrier to protect DNA from degradation by DNase I
[13,14]. To demonstrate that LMWP could protect pDNA
from nuclease degradation, the DNase I protection assay
was conducted by incubating the plasmid/LMWP complex
with DNase I. As shown by the results from agarose
gel electrophoresis (Figure 4), naked DNA was destroyed
after 10 min of incubation with DNase I (Figure 4, left
column). However, pDNA combined with LMWP even at
a charge ratio 1 : 2 (−/+) was not destroyed after more
than 80 min of incubation with DNase I (Figure 4, right
column). Therefore, it was clear that LMWP could protect
plasmid DNA from the degradation by DNase I.
In vitro transfection assay
The most effective charge ratio of pDNA/LMWP in cell
transfection was determined by using the transfection
assay of pSV-β-galactosidase into the 293T cells. As
shown in Figure 5A, at a charge ratio of 1 : 2 (−/+),
the transfection efficiency increased with increasing
the plasmid DNA content. A further experiment was
conducted by maintaining the plasmid content at 5 µg
while altering the charge ratio from 1 : 2 to 1 : 30.
Transfection efficiency was seen to increase to a maximum
when the charge ratio of the complex was raised to
1 : 10 (−/+) (Figure 5B). Further increase in the charge
ratio of the complex above 1 : 20 (−/+) resulted in no
further increase in transfection efficiency. Conversely, the
transfection efficiency actually decreased when the charge
ratio of the complex was increased above 1 : 20 (−/+).
This reduced transfection efficiency at a charge ratio above
1 : 20 (−/+) could be due to an aggregation of particles.
Nevertheless, the efficiency of transfection to 293T cells in
the presence of LMWP was markedly higher than that of
naked DNA alone. In addition, the transfection efficiency
of LMWP/DNA was compared with that of TAT/DNA.
As seen in Figure 5C, transfection efficiency was almost
similar for both complexes, which was in agreement with
results observed by the cellular trafficking assay. In this
regard, LMWP appears to be capable of delivering as
much gene into the cells as TAT. To further compare the
transfection efficiency, experiments were conducted by
using polyethyleneimine (PEI) with a similar molecular
weight to LMWP as the DNA carrier. PEI is a water-
soluble and cationic gene carrier and is known to be by
far the most potent carrier of pDNA internalization into
cells [15,16]. To perform the experiments, various charge
Naked DNA
DNase I
Incubation time (min) 0 10 20 40 60 80 10 20 40 60 80
pDNA/LMWP
complex
Figure 4. DNase I protection assay with the pDNA/LMWP complex. The pDNA/LMWP complex was prepared as described in
‘Materials and methods’ section. The complex solution was incubated with 50 units of DNase I for 10, 20, 40, 60, and 80 min. After
incubation, DNA was analyzed by 1% agarose gel electrophoresis
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Figure 5. Transfection efficiency of pDNA/LMWP complex in 293T cells. Transfection efficiency was measured using the colorimetric
β-galactosidase enzyme activity assay (ONPG assay). (A) Effects of the plasmid DNA content on the transfection efficiency. The
charge ratio of the pDNA/LMWP was adjusted to (−/+) 1 : 2. (B) Effects of the charge ratio (−/+) on the transfection efficiency.
Plasmid DNA content was adjusted to 5 µg. (C) Comparison of the transfection efficiency between pDNA/LMWP complexes and the
pDNA/TAT complex at a charge ratio of 1 : 5 (−/+). (D) Comparison of the transfection efficiency between pDNA/LMWP complexes
and various charge ratios (−/+) of pDNA/PEI complexes. Similar molecular weight of PEI (2000 Da) to LMWP (1880 Da) was used
for comparison. The data are expressed as mean ± standard deviation of four experiments. ∗p < 0.05, as compared with that of
plasmid DNA and that of a PEI complex at the same charge ratio
ratios of pDNA/PEI complexes were transfected into
293T cells. Figure 5D shows that at a charge ratio of 1 : 5,
the pDNA/PEI complex yielded the highest transfection
efficiency. At this charge ratio, however, it is clearly seen
that LMWP mediates a higher transfection efficiency (i.e.
by 26%) than PEI. Similarly, at a charge ratio (−/+)
of 1 : 10, which is the ratio for achieving the maximum
transfection efficiency for LMWP, transfection efficiency
of the pDNA/LMWP complex was markedly higher than
that of the pDNA/PEI complex. Since at a charge ratio
(−/+) of 1 : 10 the gene carriers might induce cytotoxicity
to the cells, cytotoxicity of each carrier and its associated
complex was examined.
Cytotoxicity measurement of LMWP
Although the in vivo safety of LMWP has already been
demonstrated previously [18–20], an MTT assay was
still conducted to determine the cytotoxicity of LMWP.
The cytotoxicity of LMWP by itself without plasmid DNA
was first evaluated. Figure 6 shows that cells treated
with LMWP yielded almost an identical viability in
comparison to that without the treatment whereas cells
treated with PEI introduced cytotoxicity to the cells by
reducing the cell viability by 35%. It should be noted


















Figure 6. Cytotoxicity of either LMWP or PEI to 293T cells. Cells
were plated on 96 wells and exposed to LMWP, pDNA/LMWP
complex, PEI, or pDNA/PEI complex. Cytotoxicity test was
conducted by MTT colorimetric assay as described in the
‘Materials and methods’ section. The data are expressed as
mean ± standard deviation of four experiments. ∗p < 0.05, as
compared with that of PEI or PEI complex, ∗∗p < 0.05, compared
with that with control
that the toxicity of cationic polymers has always been
a concern in their use as gene carriers. In addition,
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a greater toxicity for some polymers when applied in
the absence of pDNA has been noticed [17]. When
both pDNA/LMWP and pDNA/PEI complexes (5 µg of
pDNA, charge ratio 1 : 10) were added to 293T cells,
as seen in Figure 6, only approximately 55% of cells
were viable after incubation with pDNA/PEI, whereas
negligible cytotoxicity was observed after incubation with
the pDNA/LMWP complex. This lack of cytotoxicity of
LMWP could be very beneficial for its use as a carrier in
in vivo gene therapy.
Discussion
Peptide carriers are one of the most promising tools
for delivering biologically active molecules into cells
[11,12,27–29]. In the present study, LMWP fractions
were evaluated as possible carriers for gene delivery pur-
poses. Five LMWP fractions, denoted TDSP 1–5 with
different amino acid sequences and, more precisely, dif-
ferent arginine content, were obtained by enzymatically
digesting protamine with thermolysine (Table 1). In our
previous studies, these LMWP peptides were demon-
strated to retain the heparin-neutralizing capability and
yet be devoid of the toxic effects of protamine [18–20].
In addition, such LMWP peptides displayed a signifi-
cantly reduced level of immunogenicity (i.e. the ability to
induce the production of antibodies) and antigenicity (i.e.
the ability to cross-react with antiprotamine antibodies),
which are the two principal events in protamine-induced
imunotoxicity [18–20]. This current study is therefore
focused on the potential of utilizing LMWP as a carrier for
delivering DNA into cells. Previous studies have demon-
strated the feasibility of utilizing protamine as a possible
gene carrier due to its ability to condense pDNA [12].
This finding implicates that LMWP could have a similar
gene-condensing ability to protamine, since they possess
identical heparin-neutralization efficiency. Recently, a
number of investigators have reported the unprecedented
cell-translocating activity for TAT or other arginine-rich
peptides [30–32]. Since, as indicated above, LMWP is
rich in arginine content and has a structural similarity to
TAT, it may be used as a potent transmembrane carrier
for gene delivery. Although both TDSP 4 and TDSP 5 were
found to possess the highest degree of heparin affinity,
the current study was focused solely on TDSP 5 because it
possesses an arginine content and molecular weight that
are identical to those of TAT.
Results presented in this paper indicate that cell
internalization mediated by LMWP is almost as potent
as that of TAT. It should be pointed out that TAT has
been shown to translocate through the cell membranes
via a receptor-independent pathway [21,22]. It has also
been demonstrated that arginine-rich peptides possess
a translocation activity similar to that of TAT(48–60)
[21–23,30–32]. Indeed, peptides with more than six
arginine sequences have been reported to follow the
same pathway as TAT, suggesting that the conventional
endocytosis pathway does not play a crucial role in the cell
translocation for these arginine-rich peptides [30–32].
On the other hand, lysine-rich peptides [31], despite
containing higher positive charges, have displayed lower
degree of internalization than arginine-rich peptides
under the same experimental period, suggesting that
arginine residues could be responsible for this rapid
and receptor-independent translocalization behavior. As
shown earlier, LMWP has 10 arginine residues in its
structure (VSRRRRRRGGRRRR), and is made of two
arginine clusters connected through two glycine residues,
which is similar to that of TAT. As a consequence, our
results show that LMWP followed a similar transcellular
localization to that of TAT up to 1 h. Confocal microscopic
analysis of these two peptides also confirmed the
cytoplasmic (in 15 min) and nuclear localization (in
1 h) of these peptides with a lower sign of adhesion
to the cell membranes (Figure 1). Internalization of these
peptides was not inhibited at 4 ◦C (data not shown),
confirming the presence of a similar receptor-independent
translocalization mechanism for LMWP. A maximum
(80–90%) cell uptake of both TAT and LMWP occurred at
the 30-min mark, which was in good agreement with data
reported elsewhere for the arginine-rich peptides [21,30].
Although the exact mechanism for cellular uptake of
these peptides has not been fully elucidated yet, a
recognition mechanism based on several hypotheses has
been suggested [30–32]. In this mechanism, it is proposed
that uptake of arginine-rich peptide is mediated by the
guanidine head group in the arginine, the formation of a
hydrogen bond between arginine and the lipid phosphate
on the membrane, or the interaction of arginine with
extracellular matrices such as heparan sulfate [30–32].
The uptake of LMWP, albeit needing further investigation,
could be related to these aforementioned receptor-
independent uptake mechanisms.
Current methods of protein delivery based on the use of
these protein transduction domain (PTD) peptides require
chemical or biological cross-linking of these peptides
with the target protein [29]. Delivery of gene products
conducted in the current presentation, however, adopted
simple complexation of the peptide with pDNA, which
could offer a full retention of the biological activity
of pDNA. Simple complexation of pDNA with LMWP
yielded a nano-sized particle even at a low charge ratio,
condensing pDNA to a favorable size for cell uptake. It
has been well documented that particles within a size
range between 100–200 nm can be favorably taken up
by the cells [13,14]. The current study demonstrates
that LMWP with a molecular weight around 2000 Da
can sufficiently condense DNA to this appropriate size
range. Other reports dealing with condensation of DNA
with several condensing peptides were also conducted
with a couple of thousand molecular weight of peptide
sequence. In addition, a similar result was observed from
a similar molecular weight of PEI/DNA complexation,
which has an even smaller particle size at the charge
ratio of 1 : 1. Gel retardation results also corroborate the
formation of a stable complex between LMWP and DNA
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at a charge ratio (−/+) = 1 : 1. Aside from condensing
DNA, LMWP also increases the surface potential of the
pDNA complexes, thereby enhancing its interaction with
the cell surface membrane. In addition, the membrane-
translocating activity of LMWP could facilitate the cellular
uptake of the DNA/LMWP complex. From this result,
once the complex surface charge had reached 25 mV
after neutralization, the addition of more peptide did
not produce a significant increase in the surface zeta
potential (up to 35 mV) since the peptide itself has a
small molecular weight. However, in terms of transfection
efficiency, this increase in the amount of surface LMWP
can increase the cellular uptake of plasmid DNA since
LMWP acts not only as a condensing agent, but also as a
translocalizing carrier similar to TAT. A previous report
also indicated that the increase in the surface molecule of
TAT could induce increase of delivery of molecules into
the cells.
Results presented in this paper indicate that LMWP
possesses a high translocalization capability similar to
that of TAT, as confocal microscopy analyses show that
FITC-labeled DNA molecules are in the nucleus and
cytoplasm when combined with LWMP to form a complex
whereas no fluorescence is observed in the cytoplasm
using the FITC-labeled naked DNA. Reports by other
investigators have indicated that polyfection with PEI
and with the DNA/Lipofectamine complex could induce
nuclear distribution after 4 h of incubation [16,27,29].
Although the current cell uptake study did not examine
such an event for that long (i.e. >4 h), it nevertheless
demonstrated that LMWP could deliver pDNA into cells in
an equally efficient manner within a much shorter period
of time by a simple complexation with DNA. In addition, a
degree of fluorescence was seen in the nucleus, implying
a possible early nuclear localization of the complex. This
early nuclear localization process can be explained by the
fact that the pDNA/LMWP complex is delivered directly
into the cytoplasm by the receptor-independent cell
uptake, whereas other cationic polyplexes are delivered
by the receptor-mediated (or adsorptive) endocytosis that
requires a further endosomal release step inside the cell.
It is not clear whether the pDNA travels inside the cell
as a complex with LMWP or a dissociated form from
the complex. Further experiments using fluoro-labeled
LMWP to study the subcellular trafficking kinetics of the
pDNA/LMWP complex and the dissociation kinetics of the
DNA from the complex are currently underway in our
laboratory.
The pDNA/LMWP complex showed a significantly
higher transfection efficiency compared with that of the
pDNA/PEI complex. As reported by other investigators,
the cationic pDNA/PEI complexes were taken into the
cells via an endocytotic mechanism, whereby in the
endosomes the complexes were disrupted and pDNA was
then released into the cytosol. On the other hand, LMWP-
condensed pDNA was taken directly into the cytosol,
and protected from lysosomal and DNase degradation,
thereby achieving a significantly increased transfection
efficiency. It should be pointed out that the transfection
efficiency was almost identical to that of the pDNA/TAT
complex, reflecting the similar transfecting capacity of
LMWP to TAT.
Besides the advantages reported above, our previous
studies also demonstrate that LMWP is nontoxic in vitro
as well as in vivo [18–20]. It should be pointed out that
the toxicity of cationic polymers such as PEI is always
a concern in their use as gene carriers. Despite the fact
that the toxicity of the formed complex could be relieved
due to charge neutralization of the cationic polymer by
plasmid DNA, the polymer would remain toxic after the
detachment of pDNA. In this regard, the lack of toxicity
for LMWP even without DNA complexation could be a
strong argument for LMWP as a carrier for gene delivery
purposes.
Conclusions
Overall, preliminary results presented in this paper
demonstrate the feasibility of utilizing LMWP as an
efficient carrier for delivery of therapeutic gene or even
proteins. Data shows that LMWP can translocalize into
the cells and nucleus in a high efficiency comparable to
that of TAT. In addition, LMWP can form a stable complex
with plasmid DNA to efficiently deliver DNA into cells and
protect plasmid DNA from nuclease attack. Furthermore,
LMWP displays a higher transfection efficiency and yet
lower toxicity than any existing polycationic carriers
including PEI in 293T cells. Detailed investigations of the
cellular uptake mechanism, nuclear localization, and in
vivo transfection efficiency of the pDNA/LMWP complex
are currently in progress in our laboratory.
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